



156-158 Buckingham Palace Road, London, SW1W 9TR
Tel: +44 (0)20 7259 8482 – Fax: +44 (0)20 7259 8480

InterPharm Investments appoints Salvatore Barbagallo to Executive Committee

30th June 2011. InterPharm Investments Ltd, a London-based 'search and development' company focussing on medical foods and dietary supplements, has appointed Salvatore Barbagallo to the Executive Committee. Salvatore joins as a Scientific Advisor, alongside Elaine Evans, CEO of InterPharm, and Claudio Antico, CEO of InterPharm's affiliated company in Italy, InterAlia srl.

Salvatore Barbagallo's experience encompasses both commercial and R&D aspects of Rx pharmaceuticals. After 18 years covering various sales and marketing roles at leading pharmaceutical companies (Upjohn, Cyanamid, Lederle), Salvo became Director of the Vaccines business unit at Lederle-Praxis, then moved into Licensing & Business Development at Wyeth (Rome), where he led a number of divestment and in-licensing projects for the Italian market over an 8 year period. Always keen to take on a new challenge, he then became R&D Project Leader at Wyeth's EDSM Research centre in Catania. Over his 5 years in this role, he led collaborative research projects with European Universities, MUR (Italian Ministry of University & Research) and the Italian National Council of Research. Salvo holds a degree *magna cum laude* in Chemistry and a degree in Pharmacy from the University of Catania, in his native Italy. He brings to InterPharm not only his broad experience from the pharma industry, but a channel into the scientific community which yields a continuing stream of potential new product development opportunities.

InterPharm aims to build a portfolio of patented products meeting three key criteria: they can be brought to market quickly (e.g. medical foods, dietary supplements, medical devices); they can be promoted for use in a medical condition identified by specialist physicians or dentists; and they can be purchased without a prescription. Through co-financing, InterPharm supports the development of such products in exchange for rights for specified territories.

For further information, contact InterPharm's CEO Elaine Evans at:

eevans@interpharminvestments.com

About InterPharm Investments Ltd www.interpharminvestments.com

InterPharm Investments Ltd is a UK-based 'search and development' company building a pipeline of patent-protected products which can be developed and commercialised as medical foods, dietary supplements or medical devices. InterPharm's product portfolio includes licensed-in products sold through its affiliates or subsidiary companies in local markets, starting with InterAlia srl in Italy.

About InterAlia srl www.interalia.it

InterAlia srl is an Italian affiliate of InterPharm. InterAlia's first product is Hali-Z, a patented zinc-based lozenge formulation for enhancement of oral hygiene. InterAlia is presently building a portfolio of products in oral healthcare, promoted nationally at pharmacy level and to dentists. InterAlia will diversify its therapeutic focus in line with InterPharm's pipeline.